ImmunoGen, Inc. (IMGN) Can’t Be More Safe. Trades Significantly Higher

February 20, 2018 - By Jan Rainey

Investors sentiment decreased to 1.16 in Q3 2017. Its down 0.04, from 1.2 in 2017Q2. It dived, as 16 investors sold ImmunoGen, Inc. shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported.
Deutsche Bank & Trust Ag has invested 0.01% in ImmunoGen, Inc. (NASDAQ:IMGN). Art Advisors Ltd Liability Co has 166,036 shares. California Employees Retirement System has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 111,500 shares. Franklin Res Incorporated has invested 0.01% in ImmunoGen, Inc. (NASDAQ:IMGN). Trexquant Invest Limited Partnership invested in 104,633 shares. Lpl Fincl Llc holds 0% or 51,776 shares in its portfolio. Sei has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Moreover, Jfs Wealth Advsr has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Ameritas Invest reported 0% in ImmunoGen, Inc. (NASDAQ:IMGN). 5,300 are owned by Whittier Tru. Redmile Group Ltd Liability reported 8.06 million shares stake. Invesco Ltd stated it has 949,288 shares. Chicago Equity Prns Limited Co invested 0.12% in ImmunoGen, Inc. (NASDAQ:IMGN). 65,408 were reported by Manufacturers Life Ins Co The. Geode Capital Management Ltd Liability Com holds 884,550 shares.

Since September 13, 2017, it had 0 insider buys, and 3 insider sales for $730,210 activity. Shares for $252,457 were sold by BARROWS CRAIG. Berkenblit Anna sold $10,500 worth of stock or 1,500 shares.

The stock of ImmunoGen, Inc. (NASDAQ:IMGN) is a huge mover today! The stock increased 1.60% or $0.18 during the last trading session, reaching $11.45. About 2.55 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since February 20, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.
The move comes after 9 months positive chart setup for the $1.51 billion company. It was reported on Feb, 20 by Barchart.com. We have $12.48 PT which if reached, will make NASDAQ:IMGN worth $136.26 million more.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen has $24 highest and $500 lowest target. $13.63’s average target is 19.04% above currents $11.45 stock price. Immunogen had 28 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was upgraded by Jefferies on Wednesday, November 25 to “Buy”. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has “Buy” rating given on Monday, October 2 by RBC Capital Markets. As per Friday, September 8, the company rating was maintained by Jefferies. As per Sunday, August 6, the company rating was maintained by Jefferies. The rating was maintained by Jefferies with “Buy” on Monday, June 26. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, April 29. As per Tuesday, October 10, the company rating was maintained by Jefferies. The firm has “Hold” rating by Cowen & Co given on Sunday, June 4. The firm earned “Buy” rating on Thursday, February 8 by RBC Capital Markets. The firm has “Buy” rating given on Thursday, February 1 by Canaccord Genuity.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: Streetinsider.com which released: “Form 8-K IMMUNOGEN INC For: Feb 09” on February 09, 2018, also Seekingalpha.com with their article: “ImmunoGen Price Run-Up Driven By Potential Clinical Trial Data” published on February 06, 2018, Fool.com published: “Why ImmunoGen Inc. Pulled Back Today” on February 05, 2018. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: Streetinsider.com and their article: “Form 8-K IMMUNOGEN INC For: Jan 19” published on January 24, 2018 as well as Fool.com‘s news article titled: “What’s Behind ImmunoGen Inc.’s Brief Dip on Tuesday?” with publication date: February 13, 2018.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.51 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: